One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues
Jonathan G Leung, Megan Ehret, Raymond C Love & Robert O Cotes
doi : 10.1080/17512433.2023.2183192
Expert Review of Clinical Pharmacology, Volume 16, Issue 3 (2023)
Pharmacological strategies for the management of the antisocial personality disorder
Gianluca Sesso & Gabriele Masi
doi : 10.1080/17512433.2023.2181159
Antisocial personality disorder (AsPD) is a pervasive pattern of violation of others’ rights, related to the concept of psychopathy. AsPD is stable over time from adolescence, with evidence of conduct disorder (CD) before 15 years. DSM-5 included a specifier ‘with limited prosocial emotions’ (LPE), which characterizes adolescents with higher developmental vulnerability to develop AsPD.
Availability and evaluation of medication management resources for carers of people with dementia: a scoping review with an environmental scan
Gabrielle J Widjaja, Danijela Gnjidic, Alexander J Clough, Karen Watson, Kenneth Hepburn & Mouna J Sawan
doi : 10.1080/17512433.2023.2181158
There is a need for resources to guide informal carers in medication management for people with dementia. Availability of resources on medication management guidance has yet to be explored.
Safety of drugs used for the treatment of migraine during pregnancy: a narrative review
Jessica A Spiteri, Gabrielle Camilleri, Carlo Piccinni & Janet Sultana
doi : 10.1080/17512433.2023.2181157
Migraine is common in females of childbearing age and negatively impacts quality of life. The majority of those with migraine who become pregnant see an improvement in their condition but not all do. Providing evidence-based recommendations for the pharmacological management of migraine in pregnancy is challenging.
Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations
Dario Cattaneo, Deborah JE Marriott & Cristina Gervasoni
doi : 10.1080/17512433.2023.2181160
Linezolid can cause serious adverse effects including thrombocytopenia and anemia. Here, we focus specifically on linezolid-related hematological toxicity in adult patients requiring prolonged drug treatment.
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?
Andrea Marchetti, Elisa Tassinari, Matteo Rosellini, Alessandro Rizzo, Francesco Massari & Veronica Mollica
doi : 10.1080/17512433.2023.2181783
Androgen deprivation therapy (ADT) plus Androgen Receptor Target Agents (ARTAs) or docetaxel are the actual standard of care in prostate cancer (PC). Several therapeutic options are available for pretreated patients: cabazitaxel, olaparib, and rucaparib for BRCA mutations, Radium-223 for selected patients with symptomatic bone metastasis, sipuleucel T, and 177 LuPSMA-617.
Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials
Xiaoyu Sun, Suying Xu, Yiming Li, Xuemei Lv, Minjie Wei & Miao He
doi : 10.1080/17512433.2023.2188193
Poly-ADP-ribose polymerase inhibitors (PARPis) have emerged as a new class of therapeutic agents for breast cancer patients with breast cancer susceptibility gene (BRCA) mutations. However, the efficacy and toxicity of PARPis have not been clearly established.
An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry
Fabian Olsson, Simon Erridge, James Tait, Carl Holvey, Ross Coomber, Sushil Beri, Jonathan Hoare, Shaheen Khan, Mark W Weatherall, Michael Platt, James J Rucker & Mikael H Sodergren
doi : 10.1080/17512433.2023.2183841
There is a paucity of high-quality data on patient outcomes and safety after initiating treatment with cannabis-based medicinal products (CBMPs). The aim of this study was to assess the clinical outcomes and safety of CBMPs by analyzing patient-reported outcome measures and adverse events across a broad spectrum of chronic conditions.
A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China
Zhiwei Zheng, Gaofeng Zhu, Xueqiong Cao, Hongfu Cai & Huide Zhu
doi : 10.1080/17512433.2023.2188194
This study compares first-line toripalimab with chemotherapy for advanced nonsquamous non-small cell lung cancer (NSCLC) from the perspective of the Chinese healthcare system.
